Back to Search Start Over

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China

Authors :
Tao Li MD
Wen-Yu Yang BS
Ting-Ting Liu MD
Yao Li MD
Lu Liu MD
Xuan Zheng MD
Lei Zhao MD
Fan Zhang MD
Yi Hu MD
Source :
Technology in Cancer Research & Treatment, Vol 22 (2023)
Publication Year :
2023
Publisher :
SAGE Publishing, 2023.

Abstract

In the era of precision medicine, with the deepening of the research on malignant tumor driving genes, clinical oncology has fully entered the era of targeted therapy. For non-small-cell lung cancer (NSCLC), the development of targeted drugs targeting driver genes, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), has successfully opened up a new model of targeted therapy. At present, proto-oncogene rearranged during transfection (RET) fusion gene is an important novel oncogenic driving target, and specific receptor tyrosine kinase inhibitors (TKIs) targeting RET fusion have been approved. This article will review the latest research about the molecular characteristics, pathogenesis, detection, and clinical treatment strategies of RET rearrangements especially in China.

Details

Language :
English
ISSN :
15330338
Volume :
22
Database :
Directory of Open Access Journals
Journal :
Technology in Cancer Research & Treatment
Publication Type :
Academic Journal
Accession number :
edsdoj.b98c611e6ec8423ca993bee8a7ce04e1
Document Type :
article
Full Text :
https://doi.org/10.1177/15330338221148802